

PEGASUS TRIAL

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS)

Study Phase III

Purpose

This study is to be carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

The study population will include those who meet the following inclusion/exclusion criteria, some of which are:

Inclusion Criteria

- Patient who had a heart attack within 1-3 years ago and at least one risk factor: ≥ 65 yrs old. Diabetes requiring medication, Documented history of 2nd MI (>1 year ago). Angiographic evidence of multivessel CAD, and/or Chronic, non-end stage renal dysfunction.
- Females of child-bearing potential must have a negative pregnancy test at enrollment.
- Patients who are currently taking aspirin between 75 and 150 mg once daily.

Exclusion Criteria

- Patients who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start.
- Patients who have planned coronary, cerebrovascular, or peripheral arterial Revascularization (invasive surgery) at study start.

To inquire if you are eligible for this study or hear more about it, please contact:

Pentucket Medical Associates
Clinical Research Office
(978) 469-5494